Expression of uPA and uPAR is associated with the clinical course of urinary bladder neoplasms

International Journal of Cancer

Volumn 99, Issue 5, 2002, Pages 721-726

  Seddighzadeh, Maria ^a   Steineck, Gunnar ^a   Larsson, Per ^a   Wijkström, Hans ^b   Norming, Ulf ^c   Onelöv, Erik ^a   Linder, Stig ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Metastasis; mRNA expression; Survival; Urokinase; Urokinase receptor

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; MESSENGER RNA; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAVENOUS PYELOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

GENE EXPRESSION; HUMANS; MUSCLES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036100514     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10426     Document Type: Article

References (33)

1. The plasminogen activation system in tumor growth, invasion and metastasis
2. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis
3. Regulation of integrin function by the urokinase receptor
4. Urokinase-type plasminogen activator receptors associate with betal and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components
5. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin
6. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
7. Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets
8. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
9. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
10. Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines
11. Staging of bladder cancer: Is the tumor, node, metastasis system adequate?
12. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years
13. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial transitional cell neoplasms of the urinary bladder
14. Low interleukin-1α messenger RNA expression predicts decreased overall survival time of patients with urinary bladder carcinoma
15. Real time quantitative PCR
16. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer
17. Cellular receptor for urokinase plasminogen activator Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidyl-inositol
18. Insolubility and redistribution of GPI-anchored proteins at the cell surface after detergent treatment
19. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor and tissue-type PA messenger RNAs in human hepatocellular carcinoma
20. Urokinase type plasminogen activator receptor expression in colorectal neo-plasms
21. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)
22. Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2
23. Combined overexpression of urokinase, urokinase receptor and plasminogen activator inhibitor-I is associated with breast cancer progression: An immunohistochemical comparison of normal, benign and malignant breast tissues
24. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types
25. beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter
26. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines
27. Ets transcription factors: Nuclear effectors of the Ras-MAP-kinase signaling pathway
28. The mammalian Jun proteins: Redundancy and specificity
29. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator
30. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer
31. Amiloride selectively inhibits the urokinase-type plasminogen activator
32. The inhibition of urokinase by aromatic diamidines
33. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice